These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26676036)

  • 21. Protein crystallization.
    Deivanayagam C; Cook WJ; Walter MR
    Methods Mol Biol; 2007; 383():337-49. PubMed ID: 18217696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
    Buonpane RA; Moza B; Sundberg EJ; Kranz DM
    J Mol Biol; 2005 Oct; 353(2):308-21. PubMed ID: 16171815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular docking of superantigens with class II major histocompatibility complex proteins.
    Olson MA; Cuff L
    J Mol Recognit; 1997; 10(6):277-89. PubMed ID: 9770652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cloning, expression, crystallization and preliminary X-ray analysis of the first two Ig domains from human roundabout 1 (Robo1).
    Morlot C; Hemrika W; Romijn RA; Gros P; Cusack S; McCarthy AA
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2007 Aug; 63(Pt 8):689-91. PubMed ID: 17671369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superantigens. Structure, function, and diversity.
    Baker MD; Acharya KR
    Methods Mol Biol; 2003; 214():1-31. PubMed ID: 12489451
    [No Abstract]   [Full Text] [Related]  

  • 26. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity.
    Vath GM; Earhart CA; Monie DD; Iandolo JJ; Schlievert PM; Ohlendorf DH
    Biochemistry; 1999 Aug; 38(32):10239-46. PubMed ID: 10441117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules.
    Haas PJ; de Haas CJ; Poppelier MJ; van Kessel KP; van Strijp JA; Dijkstra K; Scheek RM; Fan H; Kruijtzer JA; Liskamp RM; Kemmink J
    J Mol Biol; 2005 Nov; 353(4):859-72. PubMed ID: 16213522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors.
    Papageorgiou AC; Collins CM; Gutman DM; Kline JB; O'Brien SM; Tranter HS; Acharya KR
    EMBO J; 1999 Jan; 18(1):9-21. PubMed ID: 9878045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A survey of protein-protein complex crystallizations.
    Radaev S; Li S; Sun PD
    Acta Crystallogr D Biol Crystallogr; 2006 Jun; 62(Pt 6):605-12. PubMed ID: 16699187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structure of the streptococcal superantigen SpeI and functional role of a novel loop domain in T cell activation by group V superantigens.
    Brouillard JN; Günther S; Varma AK; Gryski I; Herfst CA; Rahman AK; Leung DY; Schlievert PM; Madrenas J; Sundberg EJ; McCormick JK
    J Mol Biol; 2007 Apr; 367(4):925-34. PubMed ID: 17303163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bacterial superantigen and superantigen-like proteins.
    Fraser JD; Proft T
    Immunol Rev; 2008 Oct; 225():226-43. PubMed ID: 18837785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of soluble and membrane protein structures by X-ray crystallography.
    Lieberman RL; Peek ME; Watkins JD
    Methods Mol Biol; 2013; 955():475-93. PubMed ID: 23132076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
    Arad G; Levy R; Hillman D; Kaempfer R
    Nat Med; 2000 Apr; 6(4):414-21. PubMed ID: 10742148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling of receptor mimics that inhibit superantigen pathogenesis.
    Möllhoff M; Zanden HB; Shiflett PR; Gupta G
    J Mol Recognit; 2005; 18(1):73-83. PubMed ID: 15459942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray crystallography of agonist/antagonist-bound receptors.
    Pike AC
    Methods Mol Biol; 2009; 505():51-66. PubMed ID: 19117139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro.
    Seth A; Stern LJ; Ottenhoff TH; Engel I; Owen MJ; Lamb JR; Klausner RD; Wiley DC
    Nature; 1994 May; 369(6478):324-7. PubMed ID: 8183371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spectrophotometric methods for the determination of superantigen structure and stability.
    Cavallin A; Petersson K; Forsberg G
    Methods Mol Biol; 2003; 214():55-63. PubMed ID: 12489454
    [No Abstract]   [Full Text] [Related]  

  • 39. Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution.
    Papageorgiou AC; Quinn CP; Beer D; Brehm RD; Tranter HS; Bonventre PF; Acharya KR
    Protein Sci; 1996 Aug; 5(8):1737-41. PubMed ID: 8844860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Automated analysis of vapor diffusion crystallization drops with an X-ray beam.
    Jacquamet L; Ohana J; Joly J; Borel F; Pirocchi M; Charrault P; Bertoni A; Israel-Gouy P; Carpentier P; Kozielski F; Blot D; Ferrer JL
    Structure; 2004 Jul; 12(7):1219-25. PubMed ID: 15242598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.